GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off ; volume:20 ; number:1 ; day:12 ; month:10 ; year:2021 ; pages:1-5 ; date:12.2021
Cardiovascular diabetology ; 20, Heft 1 (12.10.2021), 1-5, 12.2021
- Urheber
-
Giugliano, Dario
Scappaticcio, Lorenzo
Longo, Miriam
Bellastella, Giuseppe
Esposito, Katherine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-021-01400-9
- URN
-
urn:nbn:de:101:1-2021122621291441929096
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Giugliano, Dario
- Scappaticcio, Lorenzo
- Longo, Miriam
- Bellastella, Giuseppe
- Esposito, Katherine
- SpringerLink (Online service)
Ähnliche Objekte (12)
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Nothing Seems Legit NSL
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β ‐Klotho‐Mediated Ferroptosis Inhibition
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Nothing Seems Legit NSL
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β ‐Klotho‐Mediated Ferroptosis Inhibition
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Nothing Seems Legit NSL
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β ‐Klotho‐Mediated Ferroptosis Inhibition